- Home
- KIDS vs RAPT Comparison
KIDS vs RAPT Comparison
Compare KIDS & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KIDS | RAPT |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.9M | 498.4M |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KIDS | RAPT |
|---|---|---|
| Price | $18.72 | $34.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $24.75 | ★ $57.00 |
| AVG Volume (30 Days) | 164.3K | ★ 399.5K |
| Earning Date | 03-03-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $227,410,000.00 | N/A |
| Revenue This Year | $16.58 | N/A |
| Revenue Next Year | $12.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.90 | N/A |
| 52 Week Low | $15.28 | $5.67 |
| 52 Week High | $27.60 | $42.39 |
Technical Indicators
Market Signals| Indicator | KIDS | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 52.44 |
| Support Level | $17.95 | $33.01 |
| Resistance Level | $19.09 | $33.24 |
| Average True Range (ATR) | 0.83 | 1.98 |
| MACD | 0.16 | -0.15 |
| Stochastic Oscillator | 54.34 | 56.78 |
Price Performance
Historical ComparisonAbout KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.